Corrigendum to "Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 Study" [Clin Therapeut 42 (12) (2020) 2254-2265].

The authors have identified some improper data within the text. The correct text has been printed below: Short-term Headache Medication Use A total of 170 patients in the eptinezumab 100 mg group, 169 in the 300 mg group, and 162 in the placebo group reported taking ≥1 day of headache medication during the 28-day baseline period for the post hoc analysis. Among these, patients in the eptinezumab groups had greater decreases in headache medication use compared with placebo as early as weeks 1–4 after treatment and across 24 weeks of treatment. When stratified by baseline use (1–9 days vs ≥ 10 days per month), greater improvements were observed in the subgroup with the higher baseline use. At week 24, reductions in patients with baseline use of 1–9 days per month were −2.4, −2.7, and −1.6 days in the eptinezumab 100 mg, 300 mg, and placebo groups, respectively; reductions in patients with baseline use of ≥10 days per month were −4.0, −7.4, and −4.1 days, respectively. Eptinezumab for the Prevention of Episodic Migraine: Sustained Effect Through 1 Year of Treatment in the PROMISE-1 StudyClinical TherapeuticsVol. 42Issue 12PreviewThe Prevention of Migraine via Intravenous ALD403 Safety and Efficacy 1 (PROMISE-1) study was a phase III, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, tolerability, and pharmacokinetic properties of repeat intravenous (IV) doses of the calcitonin gene–related peptide‒targeted monoclonal antibody eptinezumab (ALD403) for migraine prevention in adults with episodic migraine. Here we present the results of PROMISE-1 through 1 year of treatment (up to 4 doses). Full-Text PDF Open Access